Rocket Pharmaceuticals, Inc. Net Change in Cash
Rocket Pharmaceuticals, Inc. (RCKT) reported Net Change in Cash of $153.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-11
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $153.00M, a 764.62% increase year-over-year.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $29.57M.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $21.54M, a 51.59% decline year-over-year.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$19.88M.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $48.92M.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$50.24M, a 165.74% decline from fiscal 2015.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $76.42M.
- Rocket Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$9.18M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $153.00M 10-Q · filed 2018-05-11 | $182.57M derived: sum of 2 quarters · filed 2018-05-11 | $204.10M derived: sum of 3 quarters · filed 2018-05-11 | $184.22M derived: sum of 4 quarters · filed 2018-05-11 | |
| 2017-12-31 | $29.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $51.11M derived: sum of 2 quarters · filed 2018-03-07 | $31.23M derived: sum of 3 quarters · filed 2018-03-07 | $48.92M 10-K · filed 2018-03-07 | |
| 2017-09-30 | $21.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.65M derived: sum of 2 quarters · filed 2017-11-08 | $19.35M 10-Q · filed 2017-11-08 | -$33.86M derived: sum of 4 quarters · filed 2018-05-11 | |
| 2017-06-30 | -$19.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$2.19M 10-Q · filed 2017-08-03 | -$55.39M derived: sum of 3 quarters · filed 2018-05-11 | -$10.91M derived: sum of 4 quarters · filed 2018-05-11 | |
| 2017-03-31 | $17.70M 10-Q · filed 2018-05-11 | -$4.53M 10-Q · filed 2017-05-10 | -$35.51M derived: sum of 2 quarters · filed 2018-05-11 | $8.97M derived: sum of 3 quarters · filed 2018-05-11 | -$11.21M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | -$53.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$8.72M derived: sum of 2 quarters · filed 2018-03-07 | -$28.91M derived: sum of 3 quarters · filed 2018-03-07 | -$50.24M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $44.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $24.30M derived: sum of 2 quarters · filed 2017-11-08 | $2.96M 10-Q · filed 2017-11-08 | -$6.24M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2016-06-30 | -$20.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$41.52M 10-Q · filed 2017-08-03 | -$50.73M derived: sum of 3 quarters · filed 2017-08-03 | -$10.49M derived: sum of 4 quarters · filed 2017-08-03 | |
| 2016-03-31 | -$21.34M 10-Q · filed 2017-05-10 | -$30.54M derived: sum of 2 quarters · filed 2017-05-10 | $9.69M derived: sum of 3 quarters · filed 2017-05-10 | $5.57M derived: sum of 4 quarters · filed 2017-05-10 | |
| 2015-12-31 | -$9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $31.03M derived: sum of 2 quarters · filed 2017-03-16 | $26.90M derived: sum of 3 quarters · filed 2017-03-16 | $76.42M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $40.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $36.11M derived: sum of 2 quarters · filed 2016-11-09 | $85.63M 10-Q · filed 2016-11-09 | $83.89M derived: sum of 4 quarters · filed 2016-11-09 | |
| 2015-06-30 | -$4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $45.39M 10-Q · filed 2016-08-10 | $43.66M derived: sum of 3 quarters · filed 2016-08-10 | $40.13M derived: sum of 4 quarters · filed 2016-08-10 | |
| 2015-03-31 | $49.52M 10-Q · filed 2016-05-11 | $47.78M derived: sum of 2 quarters · filed 2016-05-11 | $44.26M derived: sum of 3 quarters · filed 2016-05-11 | $42.20M derived: sum of 4 quarters · filed 2016-05-11 | |
| 2014-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -$5.26M derived: sum of 2 quarters · filed 2016-03-23 | -$7.32M derived: sum of 3 quarters · filed 2016-03-23 | -$9.18M 10-K · filed 2016-03-23 | |
| 2014-09-30 | -$3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$5.58M derived: sum of 2 quarters · filed 2015-11-12 | -$7.44M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$3.91M 10-Q · filed 2015-08-07 | |||
| 2014-03-31 | -$1.85M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |